Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines

Carcinogenesis

Volumn 21, Issue 5, 2000, Pages 943-951

  Rakba, Nafissa ^a   Loyer, Pascal ^a   Gilot, David ^a   Delcros, Jean Guy ^b   Glaise, Denise ^a   Baret, Paul ^c   Pierre, Jean Louis ^c   Brissot, Pierre ^a   Lescoat, Gérard ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b CNRS   (France)

^c UNIVERSITÉ JOSEPH FOURIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; IRON; IRON CHELATING AGENT; TRENSOX; UNCLASSIFIED DRUG; ZINC;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA REPLICATION; DNA SYNTHESIS; DOSE TIME EFFECT RELATION; FLOW CYTOMETRY; HEPATOMA CELL; HUMAN; HUMAN CELL; MITOSIS INDEX; PRIORITY JOURNAL;

EID: 0034069521     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/21.5.943     Document Type: Article

References (31)

1. Deugnier, Y.M., Charalambous, P., Le Quilleuc, D., Turlin, B., Searle, J., Brissot, P., Powell, L.W. and Halliday, J.W. (1993) Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology, 18, 1363-1369.
2. Hsing, A.W., McLaughlin, J.K., Olsen, J.H., Mellemkjar, L., Wacholder, S. and Fraumeni, J.F. (1995) Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int. J. Cancer, 60, 160-162.
3. Chenoufi, N., Loréal, O., Drénou, B., Cariou, S., Hubert, N., Leroyer, P., Brissot, P. and Lescoat, G. (1995) Iron may induce DNA synthesis and repair in rat hepatocytes stimulated by EGF/pyruvate. J. Hepatol., 26, 650-658.
4. Hann, H.W.L., Stahlhut, M.W. and Blumberg, B.S. (1988) Iron nutrition and tumor growth: decreased tumor growth in iron deficient mice. Cancer Res., 48, 4168-4170.
5. Thompson, H.J., Kennedy, K., Witt, M. and Juzefyk, J. (1991) Effect of dietary iron deficiency or excess on the induction of mammary carcinogenenis by 1-methyl-1-nitrosourea. Carcinogenesis, 12, 111-114.
6. Tarao, K., Shimizu, A., Ohkawa, S., Harada, M., Ito, Y., Tamai, S. and Kuni, Y. (1992) Development of hepatocellular carcinoma associated with increases in DNA synthesis in the surrounding cirrhosis. Gastroenterology, 103, 595-600.
7. Ballardini, G., Groff, P., Zoli, M., Bianchi, G., Giostra, F., Francesconi, R., Lenzi, M., Zauli, D., Cassani, F. and Bianchi, F. (1994) Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J. Hepatol., 20, 218-222.
8. Soyano, A., Chinea, M. and Romano, E.L. (1984) The effect of desferrioxamine on the proliferative response of rat lymphocytes stimulated with various mitogens in vitro. Immunopharmacology, 8, 163-169.
9. Polson, R.J., Jenkins, R., Lombard, M., Williams, A.C., Roberts, S., Nouri-Aria, K., Williams, R. and Bomford, A. (1990) Mechanisms of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine. Immunology, 1990, 176-181.
10. Richardson, D.R. and Milnes, K. (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood, 89, 3025-3038.
11. Chenoufi, N., Baffet, G., Drénou, B., Cariou, S., Desille, M., Clément, B., Brissot, P., Lescoat, G. and Loréal, O. (1997) Deferoxamine arrests in vitro the proliferation of porcine hepatocyte in G1 phase of the cell cycle. Liver, 18, 60-67.
12. Chenoufi, N., Drénou, B., Loréal, O., Pigeon, C., Brissot, P. and Lescoat, G. (1998) Antiproliferative effect of deferiprone on the HepG2 cell line. Biochem. Pharmacol., 56, 431-437.
13. Reddel, R.R., Hedley, D.W. and Sutherland, R.L. (1985) Cell cycle effects of iron depletion on T-47D human breast cancer cells. Exp. Cell Res., 161, 277-284.
14. Hoyes, K.P., Hider, R.C. and Porter, J.B. (1992) Cell cycle synchronisation and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res., 52, 4591-4599.
15. Kulp, K.S., Green, S.L. and Vulliet, P.R. (1996) Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp. Cell Res., 229, 60-68.
16. Hileti, D., Panayiotidis, P. and Hoffbrand, A.V. (1995) Iron chelators induce apoptosis in proliferating cells. Br. J. Haematol., 89, 181-187.
17. Kovar, J., Stunz, L.L., Stewart, B.C., Kriegerbeckova, K., Ashman, R.F. and Kemp, J.D. (1997) Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13. Pathobiology, 65, 61-68.
18. Rakba, N., Aouad, F., Henry, C., Caris, C., Morel, I., Baret, P., Pierre, J.L., Brissot, P., Ward, R.J., Lescoat, G. and Crichton, R. (1998) Iron mobilisation and cellular protection by a new synthetic chelator O-Trensox. Biochem. Pharmacol., 55, 1797-1806.
19. II) potentially suitable for plant nutrition and iron chelation therapy. J. Am. Chem. Soc., 117, 9760-9761.
20. Caris, C., Baret, P., Béguin, C., Serratrice, G., Pierre, J.L. and Laulhère, J.P. (1995) Metabolization of iron by plant cells using O-Trensox, a high-affinity abiotic iron-chelating agent. Biochem. J., 312, 879-885.
21. Knowles, B.B., Howe, C.C. and Aden, D.P. (1980) Human hepatocellular carcinoma cell lines secrete the major proteins and hepatitis B antigen. Science, 209, 497-499.
22. Glaise, D., Ilyin, G., Loyer, P., Cariou, S., Bilodeau, M., Lucas, J., Puisieux, A., Ozturk, M. and Guguen-Guillouzo, C. (1998) Cell cycle gene regulation in reversibly differentiated new human hepatoma cell lines. Cell Growth Differ., 60, 19-26.
23. Stennicke, H.R. and Salvesen, G.S. (1997) Biochemical characteristics of caspases-3, -6, -7 and -8. J. Biol. Chem., 272, 25719-25723.
24. Rouquet, N., Carlier, K., Briand, P., Wiels, I.J. and Joulin, V. (1996) Multiple pathways of Fas-induced apoptosis in primary culture of hepatocytes. Biochem. Biophys. Res. Commun., 229, 27-35.
25. Brodie, C., Siriwardana, G., Lucas, J., Schleicher, R., Terada, N., Szepesi, A., Gelfand, E. and Seligman, P. (1993) Neuroblastoma sensitivity to growth inhibition by desferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res., 53, 3968-3975.
26. Lucas, J.J., Szepesi, A., Domenico, J., Takase, K., Tordai, A., Terada, N. and Gelfand, E.W. (1995) Effects of iron depletion on cell cycle progression in normal human T lymphocytes: selective inhibition of the appearance of the cyclin A-associated component of the p33cdk2 kinase. Blood, 86, 2268-2280.
27. Nyholm, S., Mann, G.J., Johansson, A.G., Bergeron, R.J., Graslund, A. and Thelander, L. (1993) Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J. Biol. Chem., 268, 26200-26205.
28. Cooper, C.E., Lynagh, G.R., Hoyes, K.P., Hider, R.C., Cammack, R. and Porter, J.B. (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem., 271, 20291-20299.
29. Nocentini, G., Federici, F., Franchetti, P. and Barzi, A. (1993) 2,2′-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit. Cancer Res., 53, 19-26.
30. Oblender, M. and Carpentieri, U. (1991) Growth, ribonucleotide reductase and metals in murine leukemic lymphocytes. J. Cancer Res. Clin. Oncol., 117, 444-448.
31. Sunderman, F.W. (1995) The influence of zinc on apoptosis. Ann. Clin. Lab Sci., 25, 134-142.